Asenapine

MECHANISM OF ACTION

Asenapine is an atypical antipsychotic that acts as a serotonin–dopamine antagonist (SDA). It blocks dopamine D2/D3 and multiple serotonin receptors, helping reduce psychotic symptoms and stabilize mood while lowering the risk of movement-related side effects. It also affects adrenergic and histamine receptors, and sublingual administration allows rapid absorption and effective bioavailability.

PHARMACOKINETICS

Absorption

Asenapine is administered sublingually, which allows it to be rapidly absorbed through the oral mucosa. This route bypasses first-pass metabolism, resulting in higher and more consistent bioavailability compared to oral swallowing. Peak plasma concentrations are typically reached within 0.5 to 1.5 hours after administration.

Distribution

Asenapine is widely distributed in the body and is highly protein-bound (~95%) in plasma. It crosses the blood-brain barrier to exert its effects on central nervous system receptors. The apparent volume of distribution is approximately 13–20 L/kg, reflecting extensive tissue penetration.

Metabolism

Asenapine is extensively metabolized in the liver, primarily through glucuronidation by UGT1A4 and oxidation by CYP1A2, with minor contributions from CYP3A4 and CYP2D6. Its metabolites are largely inactive, and hepatic metabolism plays a key role in determining plasma levels and drug clearance.

Elimination

Asenapine and its metabolites are primarily excreted in urine (50%) and feces (40%). The elimination half-life is approximately 24 hours, supporting once- or twice-daily dosing depending on clinical use.

PHARMACODYNAMICS

Asenapine is an atypical antipsychotic that exerts its effects by antagonizing dopamine D2 and multiple serotonin receptors (5-HT2A, 5-HT2C, 5-HT6, 5-HT7). This receptor profile helps reduce psychotic symptoms, stabilize mood, and improve negative symptoms while minimizing extrapyramidal side effects. Additional antagonism of adrenergic α1/α2 and histamine H1 receptors contributes to sedation and other central nervous system effects. Its rapid sublingual absorption allows effective plasma concentrations to be achieved quickly, supporting symptom control in schizophrenia and acute manic or mixed episodes of bipolar I disorder.

ADMINISTRATION

Asenapine is administered sublingually as a tablet, meaning it must be placed under the tongue and allowed to dissolve completely. Patients should avoid eating or drinking for at least 10 minutes after administration to ensure optimal absorption. It is typically dosed once or twice daily depending on the indication and clinical response.

DOSAGE AND STRENGTH

Asenapine is available as sublingual tablets in 2.5 mg, 5 mg, 10 mg, and 20 mg strengths. Schizophrenia (adults):  Typically 5–10 mg twice daily, depending on response and tolerability.
Bipolar I disorder (acute mania or mixed episodes, adults): Usually10 mg twice daily at treatment initiation; dose may be adjusted to 5–10 mg twice daily.

DRUG INTERACTIONS

Asenapine is mainly metabolized by CYP1A2. CYP1A2 inhibitors (e.g., fluvoxamine) can increase levels, while inducers (e.g., smoking, rifampin) can reduce efficacy. Caution with CNS depressants or antihypertensives due to additive sedation or blood pressure effects.

FOOD INTERACTIONS

Asenapine should be taken sublingually on an empty mouth. Eating or drinking for at least 10 minutes after administration can reduce its absorption and effectiveness.

CONTRAINDICATIONS

Asenapine is contraindicated in patients with a known hypersensitivity to the drug or any of its components, as allergic reactions can be severe. It should also be avoided in individuals with severe hepatic impairment due to reduced metabolism and increased risk of toxicity. Additionally, caution is warranted in elderly patients with dementia-related psychosis, as use in this population is associated with an increased risk of mortality.

SIDE EFFECTS

• Somnolence

• Dizziness

• Oral hypoesthesia

• Weight gain

• Akathisia

• Orthostatic hypotension

TOXICITY

Asenapine has a relatively low acute toxicity, but overdose can lead to severe sedation, hypotension, tachycardia, and extrapyramidal symptoms. Management is primarily supportive, including monitoring of vital signs, ensuring airway protection, and symptomatic treatment of cardiovascular or neurological effects. There is no specific antidote for Asenapine overdose, and patients should be observed until clinical stabilization.